|
|
News Breaks | | | | November 28, 2012 | | 07:38 EDT |  | CNDO | Coronado Biosciences initiates Phase 1/2 trial of CNDO-109
Coronado Biosciences announced the initiation of a phase 1/2 dose escalation trial of allogeneic natural killer, or NK, cells activated by the Company's CNDO-109 in patients in first complete remission from acute myeloid leukemia, or AML, and who are deemed high-risk for relapse. The phase 1/2 trial is a multi-center, open-label, single-dose, dose-escalating clinical study designed to examine the safety of CNDO-109 activated allogeneic NK cells, as well as the relapse-free survival and overall survival in adult patients with AML. Up to 36 patients who are in CR1 from AML at the time of enrollment, and who are at high-risk for relapse, will be infused with a preparatory regimen of cyclophosphamide and fludarabine followed by a single dose of allogeneic NK cells activated by CNDO-109. | |
|
News For CNDO From The Last 14 Days Check below for free stories on CNDO the last two weeks. |
|
|
| May 8, 2013 | | 07:23 EDT |  | CNDO | Coronado Biosciences reports Q1 EPS (35c), consensus (30c)
 Subscribe for More Information | |
|
|
|
|
|
|
